Drug Monograph
Lovastatin
Brand names: Mevacor, Altoprev (extended-release)
Pharmacokinetic Profile
Half-Life
1.1–1.7 h (parent)
Metabolism
CYP3A4 (hepatic first-pass)
Protein Binding
>95%
Bioavailability
<5% (systemic)
Volume of Distribution
Not well characterised; high hepatic selectivity
Clinical Information
Drug Class
Statin (HMG-CoA reductase inhibitor)
Available Doses
IR: 10, 20, 40 mg tablets; ER: 20, 40, 60 mg tablets
Route
Oral
Renal Adjustment
CrCl <30 mL/min: max 20 mg/day
Hepatic Adjustment
Contraindicated in active liver disease
Pregnancy
Avoid; potential fetal harm
Lactation
Not recommended
Schedule / Legal Status
Prescription only (Rx)
Generic Available
Yes
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Primary hypercholesterolaemia (types IIa and IIb) | Adults | Adjunctive to diet | FDA Approved |
| Coronary heart disease risk reduction (MI, unstable angina, revascularisation) | Adults at high CHD risk | Adjunctive to diet | FDA Approved |
| Slowing progression of coronary atherosclerosis | Adults with established CHD | Adjunctive to diet | FDA Approved |
| Heterozygous familial hypercholesterolaemia (heFH) | Adolescents 10–17 years (at least 1 yr post-menarche in girls) | Adjunctive to diet | FDA Approved |
Lovastatin was the first statin approved by the FDA in 1987, and it remains a widely used low-to-moderate intensity statin. Its primary role today is in patients who require modest LDL-C reduction (typically 20–40% depending on dose) as part of an overall cardiovascular risk reduction strategy. The 2018 AHA/ACC cholesterol guideline classifies lovastatin 40 mg as moderate-intensity statin therapy, while lovastatin 20 mg is considered low-intensity.
Off-Label Uses
Non-cardioembolic stroke prevention: Based on extrapolation from the statin class benefit in reducing ischaemic stroke risk (Evidence quality: Moderate).
Perioperative cardiac risk reduction for non-cardiac surgery: Some centres initiate statin therapy preoperatively for high-risk vascular surgery patients (Evidence quality: Low).
Dosing
Adult Dosing — Immediate-Release Tablets
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Primary hyperlipidaemia — initial therapy | 20 mg once daily | 20–40 mg once daily | 80 mg/day | Take with evening meal; titrate at 4-week intervals Evening dosing preferred as hepatic cholesterol synthesis peaks overnight |
| Moderate-intensity statin therapy for ASCVD risk | 40 mg once daily | 40 mg once daily | 80 mg/day | Corresponds to expected 30–49% LDL-C reduction (AHA/ACC 2018) May split as 20 mg BID for greater LDL lowering |
| Secondary prevention in established CHD | 20 mg once daily | 40–80 mg/day | 80 mg/day | Consider high-intensity statin if >50% LDL reduction needed BID dosing (40 mg BID) yields ~40% LDL reduction |
| Patient requiring low starting dose (elderly, mild CKD) | 10 mg once daily | 10–20 mg once daily | 20 mg/day | Consider when CrCl <30 mL/min or on interacting drugs Plasma levels ~2-fold higher in severe renal impairment |
| Co-administration with danazol, diltiazem, dronedarone, or verapamil | 10 mg once daily | 10–20 mg once daily | 20 mg/day | Hard cap due to increased myopathy risk (FDA PI) Diltiazem increases lovastatin AUC ~3.6-fold |
| Co-administration with amiodarone | 10–20 mg once daily | 20–40 mg once daily | 40 mg/day | Do not exceed 40 mg/day with amiodarone (FDA PI) |
Adolescent Dosing (heFH, ages 10–17 years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Heterozygous familial hypercholesterolaemia | 10–20 mg once daily | 10–40 mg once daily | 40 mg/day | Girls must be at least 1 yr post-menarche; titrate at 4-week intervals LDL-C must be ≥190 mg/dL or ≥160 mg/dL with positive family hx and ≥2 risk factors |
Clinical Pearl — Evening Dosing
Lovastatin IR should be taken with the evening meal. This is because hepatic cholesterol synthesis follows a diurnal pattern and peaks overnight. In clinical studies, evening dosing produced greater LDL-C reduction than morning dosing. The extended-release formulation (Altoprev) is dosed at bedtime; unlike the IR form, food decreases its bioavailability.
Pharmacology
Mechanism of Action
Lovastatin is administered as an inactive lactone pro-drug that undergoes hydrolysis in vivo to its active beta-hydroxyacid form. This active metabolite competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis that catalyses the conversion of HMG-CoA to mevalonate. By reducing intracellular cholesterol in hepatocytes, lovastatin triggers upregulation of LDL receptors on the liver cell surface, increasing clearance of circulating LDL-C. Beyond lipid lowering, statins including lovastatin demonstrate pleiotropic effects such as improved endothelial function, reduced vascular inflammation, decreased platelet aggregation, and plaque stabilisation. Lovastatin was originally isolated from the fungus Aspergillus terreus and became the first FDA-approved statin in 1987.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~30% absorbed; Tmax 2–4 h; <5% reaches systemic circulation as active inhibitors | Extensive hepatic first-pass extraction; take IR with evening meal (food increases absorption ~50%); ER (Altoprev) dosed at bedtime — food decreases its bioavailability |
| Distribution | Protein binding >95%; crosses blood–brain and placental barriers | High hepatic selectivity; placental transfer raises concern in pregnancy |
| Metabolism | CYP3A4; active metabolites include beta-hydroxyacid, 6′-hydroxy derivative | Numerous CYP3A4-mediated drug interactions; grapefruit juice can increase AUC up to 15-fold |
| Elimination | t½ 1.1–1.7 h (parent); 83% faeces, 10% urine | Short half-life necessitates evening dosing; primarily biliary excretion of drug equivalents |
Side Effects
1–10%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Flatulence | 3.7–4.2% | Most common GI complaint; typically mild and dose-independent in EXCEL trial |
| Headache | 2.5–3.3% | Rate similar to placebo (2.7%); usually transient |
| Abdominal pain | 1.6–2.0% | GI effects often improve with continued therapy |
| Diarrhea | 2.2–3.2% | Not statistically different from placebo in EXCEL study |
| Constipation | 1.9–3.2% | Dose-dependent in EXCEL; higher at 80 mg/day |
| Nausea | 2.0–2.5% | Usually resolves within 2–4 weeks of continued therapy |
| Myalgia | 1.7–2.6% | Rate comparable to placebo (~1.7%); always evaluate for true myopathy |
| Dizziness | 0.5–1.2% | Mild; generally self-limiting |
| Rash | 0.7–1.2% | Discontinue if persistent or accompanied by systemic symptoms |
| Blurred vision | 0.8–1.3% | Not associated with clinically significant lens opacities in long-term studies |
| CK elevation (≥2× ULN) | ~11% | From Phase III studies (vs 9% with cholestyramine control); attributable to noncardiac CK fraction; rule out myopathy if symptomatic |
| Transaminase elevation (>3× ULN, persistent) | 0.1–1.5% | Dose-related: 0.1% at 20 mg, 0.9% at 40 mg, 1.5% at 80 mg/day |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Myopathy (CK >10× ULN with symptoms) | <0.1% | Weeks to months; dose-dependent | Stop lovastatin immediately; check CK and renal function; only occurred at 40–80 mg/day in EXCEL |
| Rhabdomyolysis | Very rare | Variable; risk peaks with drug interactions | Emergency care; IV hydration; discontinue permanently; monitor renal function and electrolytes |
| Immune-mediated necrotising myopathy (IMNM) | Very rare | Months to years; may persist after discontinuation | Discontinue; test anti-HMG-CoA reductase antibodies; rheumatology referral; immunosuppressive therapy may be needed |
| Hepatotoxicity (symptomatic liver injury) | Rare | 3–12 months; transaminase rises are dose-related | Stop lovastatin; evaluate for alternative aetiologies; do not rechallenge if serious liver injury confirmed |
| New-onset diabetes mellitus | Uncommon (class effect) | Months to years | Continue statin (CV benefit outweighs risk per FDA); manage diabetes per guidelines |
| Cognitive impairment (memory loss, confusion) | Rare (post-marketing) | Days to years after initiation | Generally reversible within ~3 weeks of discontinuation; evaluate for non-statin causes |
Discontinuation
Discontinuation Rates
EXCEL Study (48 weeks)
4.6% vs 2.5% placebo
Top reasons: GI symptoms, transaminase elevations, muscle complaints
AFCAPS/TexCAPS (5.1 yr median)
Comparable to placebo
Note: Long-term tolerability profile was similar between lovastatin 20–40 mg and placebo groups
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| GI adverse effects | ~1.0–1.5% | Flatulence, abdominal pain, nausea; most common cause |
| Transaminase elevations (>3× ULN) | 0.1–1.5% | Dose-dependent; reverts on discontinuation |
| Musculoskeletal complaints | ~0.5–1.0% | Myalgia, muscle cramps; distinguish from true myopathy |
Managing Muscle Complaints
Muscle symptoms are the leading reason patients discontinue statin therapy. For lovastatin, check CK if the patient reports unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. CK >10× ULN with symptoms warrants immediate discontinuation. For patients with tolerable myalgia and normal CK, consider dose reduction, alternate-day dosing, or switching to a hydrophilic statin. Risk factors for statin myopathy include advanced age (≥65), female sex, uncontrolled hypothyroidism, renal impairment, and concomitant CYP3A4 inhibitors.
Drug Interactions
Lovastatin is a CYP3A4 substrate with very low systemic bioavailability. Any increase in systemic exposure substantially raises the risk of myopathy and rhabdomyolysis. Strong CYP3A4 inhibitors are contraindicated; moderate inhibitors require dose capping. Grapefruit juice in large quantities can increase lovastatin exposure up to 15-fold and should be avoided.
Major
Itraconazole / Ketoconazole / Posaconazole
MechanismStrong CYP3A4 inhibition
EffectLovastatin AUC increased >14- to 36-fold; extreme myopathy risk
ManagementContraindicated; use an alternative statin not dependent on CYP3A4 (e.g., rosuvastatin, pravastatin)
FDA PI
Major
Clarithromycin / Erythromycin / Telithromycin
MechanismStrong CYP3A4 inhibition (macrolides)
EffectMarkedly increased lovastatin levels and myopathy risk
ManagementContraindicated; use azithromycin if a macrolide is needed (no CYP3A4 inhibition)
FDA PI
Major
HIV Protease Inhibitors (ritonavir, etc.)
MechanismPotent CYP3A4 inhibition
EffectGreatly increased statin exposure; high rhabdomyolysis risk
ManagementContraindicated; switch to pravastatin, rosuvastatin, or pitavastatin
FDA PI
Major
Cyclosporine
MechanismCYP3A4 inhibition + P-gp inhibition; AUC increased 5- to 8-fold
EffectMyopathy risk substantially elevated in co-treated patients (early case series)
ManagementContraindicated; use pravastatin or fluvastatin with cyclosporine
FDA PI
Major
Gemfibrozil
MechanismInhibits glucuronidation of lovastatin acid; increases active metabolite AUC ~2.8-fold
EffectSubstantially increased myopathy risk
ManagementContraindicated; if fibrate needed, fenofibrate has lower interaction risk
FDA PI
Moderate
Diltiazem
MechanismModerate CYP3A4 inhibition; total lovastatin acid AUC increased ~3.6-fold
EffectIncreased myopathy risk at higher lovastatin doses
ManagementCap lovastatin at 20 mg/day; monitor for muscle symptoms
FDA PI
Moderate
Verapamil / Dronedarone
MechanismModerate CYP3A4 inhibition
EffectIncreased lovastatin exposure and myopathy risk
ManagementDo not exceed lovastatin 20 mg/day
FDA PI
Moderate
Amiodarone
MechanismCYP3A4 inhibition (amiodarone and its metabolite)
EffectElevated lovastatin levels; increased risk of muscle toxicity
ManagementDo not exceed lovastatin 40 mg/day
FDA PI
Moderate
Niacin (≥1 g/day)
MechanismPharmacodynamic synergy for muscle toxicity
EffectIncreased myopathy risk when combined with statin
ManagementUse with caution; weigh incremental lipid benefit against risk
FDA PI
Moderate
Colchicine
MechanismIndependent myotoxicity; additive muscle risk
EffectCases of myopathy and rhabdomyolysis reported (including fatality)
ManagementUse with caution; educate patient on muscle symptom reporting
FDA PI / Case Reports
Minor
Warfarin
MechanismPotential modest increase in anticoagulant effect
EffectPossible INR prolongation; clinical significance variable
ManagementMonitor INR more closely when initiating or changing lovastatin dose
FDA PI
Minor
Ranolazine
MechanismWeak CYP3A4 inhibition
EffectModestly increased lovastatin exposure
ManagementConsider lovastatin dose adjustment; monitor for muscle symptoms
FDA PIMonitoring
-
Lipid Panel
Baseline, 4–12 weeks after initiation, then annually
Routine Fasting lipid profile including total cholesterol, LDL-C, HDL-C, and triglycerides. Reassess adherence and lifestyle if LDL-C response less than expected. -
Liver Enzymes (ALT/AST)
Before starting therapy; repeat if clinically indicated
Routine Obtain baseline hepatic transaminases. Routine periodic monitoring no longer mandated by FDA (2012 update), but check if patient develops symptoms of liver injury (fatigue, anorexia, jaundice, dark urine). -
Creatine Kinase (CK)
When clinically indicated
Trigger-based Not required routinely. Obtain baseline CK in patients at high risk for myopathy (family history, renal impairment, hypothyroidism, multiple interacting drugs). Measure CK promptly if muscle pain, tenderness, or weakness develops. -
Fasting Glucose / HbA1c
Baseline; annually in at-risk patients
Routine Statins can modestly increase blood glucose. Monitor for new-onset diabetes, particularly in patients with pre-existing metabolic risk factors. -
Renal Function
Baseline; repeat if rhabdomyolysis suspected
Trigger-based Serum creatinine and eGFR at baseline to guide dose selection. Lovastatin exposure approximately doubles in severe renal impairment (CrCl 10–30 mL/min). -
Thyroid Function
Baseline if clinically relevant
Trigger-based Uncontrolled hypothyroidism is a predisposing factor for statin-induced myopathy. Treat hypothyroidism before initiating lovastatin.
Contraindications & Cautions
Absolute Contraindications
- Active liver disease or unexplained persistent transaminase elevations (>3× ULN)
- Pregnancy — lovastatin may cause fetal harm; discontinue immediately if pregnancy is recognised
- Breastfeeding — potential for serious adverse effects in nursing infants
- Concomitant strong CYP3A4 inhibitors: itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, erythromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, cobicistat-containing products
- Concomitant cyclosporine or gemfibrozil
- Hypersensitivity to lovastatin or any component
Relative Contraindications (Specialist Input Recommended)
- Severe renal impairment (CrCl <30 mL/min) at doses exceeding 20 mg/day — elevated plasma levels increase myopathy risk; specialist review before exceeding dose cap
- History of statin-associated myopathy or rhabdomyolysis — may re-emerge with lovastatin given shared mechanism
- Substantial alcohol consumption with pre-existing liver disease — compounded hepatotoxicity risk
Use with Caution
- Elderly patients (≥65 years) — predisposed to myopathy; plasma inhibitory activity ~45% higher in patients 70–78 years vs younger adults
- Uncontrolled hypothyroidism — correct before starting therapy, as this independently raises myopathy risk
- Patients undergoing major surgery — consider temporary discontinuation if predisposed to acute kidney injury (sepsis, hypotension, trauma)
- Concomitant moderate CYP3A4 inhibitors (diltiazem, verapamil, dronedarone, amiodarone, danazol) — strict dose caps apply
FDA Class-Wide Regulatory Warning
Statins and Myopathy/Rhabdomyolysis
All statins carry the risk of myopathy, defined as muscle pain or weakness with CK >10× ULN. In rare cases, rhabdomyolysis with myoglobinuria and acute renal failure can occur, which may be fatal. The risk is dose-related and markedly increased when statins are combined with certain interacting drugs. Patients should be warned to promptly report unexplained muscle symptoms. Lovastatin has specific dose caps when used with danazol, diltiazem, dronedarone, verapamil (max 20 mg/day) and amiodarone (max 40 mg/day).
Patient Counselling
Purpose of Therapy
Lovastatin helps lower cholesterol levels in the blood, which reduces the build-up of fatty deposits in blood vessel walls and lowers the risk of heart attack and stroke. It works best when combined with a heart-healthy diet, regular physical activity, and weight management. The medication does not cure high cholesterol — it must be taken long-term to maintain its protective effect.
How to Take
Take lovastatin immediate-release tablets with the evening meal, as the body makes most of its cholesterol at night. Swallow tablets whole. If taking the extended-release formulation (Altoprev), take at bedtime. Do not crush, chew, or split extended-release tablets. Do not consume large amounts of grapefruit juice while on lovastatin.
Muscle Pain or Weakness
Tell patient
Mild muscle aches occur in a small number of patients and are usually not serious. However, in rare cases, statin therapy can cause significant muscle damage. Report any unexplained muscle pain, tenderness, or weakness to your prescriber, especially if accompanied by fever, feeling unwell, or dark-coloured urine.
Call prescriber
If you experience persistent or worsening muscle pain, weakness, or tenderness, particularly with fever, general malaise, or dark brown urine — seek medical attention promptly.
Liver Effects
Tell patient
Your prescriber may order blood tests before and during treatment to check liver function. Serious liver problems are very rare, but you should be aware of the warning signs.
Call prescriber
If you develop unusual fatigue, loss of appetite, upper abdominal discomfort, dark urine, or yellowing of skin or eyes — contact your prescriber immediately.
GI Symptoms
Tell patient
Some patients experience gas, stomach discomfort, constipation, or diarrhea when starting lovastatin. These symptoms are usually mild and tend to improve within the first few weeks of treatment.
Call prescriber
If GI symptoms are severe, persistent beyond 4 weeks, or interfere with daily activities.
Drug and Food Interactions
Tell patient
Inform all healthcare providers that you are taking lovastatin before starting any new medication, including over-the-counter drugs and supplements. Avoid consuming large quantities of grapefruit juice. Red yeast rice supplements contain a lovastatin-like compound and should not be taken concurrently.
Call prescriber
Before starting any new antibiotic, antifungal, heart medication, or HIV treatment — some require lovastatin dose changes or substitution.
Pregnancy and Contraception
Tell patient
Lovastatin should not be taken during pregnancy as it may harm the developing baby. Women of childbearing potential should use effective contraception during treatment.
Call prescriber
If you become pregnant or plan to become pregnant — lovastatin should be stopped immediately.
Sources
Regulatory (PI / SmPC)
- Lovastatin Tablets USP — Prescribing Information. Lupin Pharmaceuticals. Revised June 2024. drugs.com/pro/lovastatin Primary reference for dosing, pharmacokinetics, drug interactions, and adverse reactions data.
- MEVACOR (lovastatin) Tablets — Full Prescribing Information. Merck & Co., Inc. FDA DailyMed Original brand label providing EXCEL study data, clinical trial efficacy tables, and AFCAPS/TexCAPS results.
- ALTOPREV (lovastatin extended-release) Tablets — Prescribing Information. Covis Pharma. Revised 03/2024. FDA DailyMed Extended-release formulation label including Altoprev-specific pharmacokinetic data and dosing.
Key Clinical Trials
- Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med. 1991;151(1):43-49. PMID: 1985608 Pivotal 8,245-patient RCT providing dose-response efficacy data and the primary adverse event profile used in the FDA label.
- Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622. doi:10.1001/jama.279.20.1615 Landmark primary prevention trial demonstrating 37% reduction in first acute coronary events with lovastatin 20–40 mg vs placebo.
- Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation. 1994;89(3):959-968. doi:10.1161/01.CIR.89.3.959 Angiographic trial showing lovastatin slowed progression of coronary lesions compared to placebo.
Guidelines
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003 Current US cholesterol management guideline classifying lovastatin 40 mg as moderate-intensity statin therapy.
- Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e52-e81. doi:10.1161/ATV.0000000000000073 Comprehensive AHA scientific statement reviewing statin safety, myopathy risk factors, and evidence on hepatic, diabetogenic, and cognitive effects.
Mechanistic / Basic Science
- Alberts AW, Chen J, Kuron G, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A. 1980;77(7):3957-3961. doi:10.1073/pnas.77.7.3957 Original discovery paper describing lovastatin (mevinolin) as a potent HMG-CoA reductase inhibitor isolated from Aspergillus terreus.
- Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517-526. doi:10.1038/nrd1112 Historical review covering the development of lovastatin from laboratory discovery to the first statin FDA approval in 1987.
Pharmacokinetics / Special Populations
- Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63(4):397-402. doi:10.1016/S0009-9236(98)90034-0 Key PK study quantifying the 15-fold increase in lovastatin AUC with double-strength grapefruit juice via CYP3A4 inhibition.
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. Lovastatin. Updated 2020. NCBI Bookshelf NIH resource summarising lovastatin hepatotoxicity patterns, dose-dependent transaminase elevations, and rare clinical liver injury.
- Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84(3):413-428. doi:10.1016/S0163-7258(99)00045-5 Review comparing statin PK properties including lovastatin’s CYP3A4 dependence, hepatic selectivity, and lipophilicity.